Dendreon.com discovery, development, commercialization of cancer treatments
About Dendreon.com
Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development, commercialization, and manufacturing of novel therapeutics that may significantly improve cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response. Dendreon is headquartered in Seattle and has manufacturing facilities in New Jersey, Georgia, and California.
Who We Are
Researchers all over the world have sought to harness the human immune system to fight cancer. Here at Dendreon, our decade-plus journey has involved more than a thousand courageous patients, more than a dozen clinical trials, and nearly one billion dollars of funding. And throughout this journey, our guiding principle has been simple: patients first.
Many of us have been affected by cancer, which is why we’re dedicated to revolutionizing the way this disease is treated. We promise to continue to build, continue to invest, and continue to do everything we can to develop more targeted therapies to help give cancer patients hope.
History
Early on, we recognized the power and potential of active cellular immunotherapy (ACI) to fight cancer. And in April 2009, we announced that the pivotal PROVENGE Phase 3 IMPACT study in men with advanced prostate cancer had met its primary endpoint of improving overall survival compared to the control arm.
On April 29, 2010, PROVENGE® (sipuleucel-T) received FDA approval for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. It is the first in a new class of cancer treatments called autologous cellular immunotherapies.
Our Products
PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. PROVENGE is designed to induce an immune response against prostate cancer. To learn more, please visit provenge.com.
We are also currently evaluating a variety of therapeutic approaches that share a common attribute: a targeted therapy platform that provides patients with new treatment options and may improve the lives of patients. For the latest news, please visit dendreon.com.
Our Philosophy
Every day, we live our mission: to transform the lives of patients through the discovery, development, and commercialization of innovative cancer treatments. Join us and share our dedication to hope.
Trust & Respect We show personal consideration and professional appreciation to others for their efforts.
Teamwork We acknowledge that our common success is greater than the sum of our individual efforts.
Open & Honest Communication We are committed to direct, open, and honest communication in all our dealings.
Work/Life Balance We are committed to finding the right balance between our work and our personal lives.
Corporate Stewardship We conduct our business with integrity by acting responsibly and with the highest ethical and social standards.
Quality & Excellence We have an uncompromising passion for excellence and quality in all we do.
Passionate Innovation We drive our commitment to target cancer and to transform lives with passion and zeal.
Working Here
We’re not just another biotech company—we’re changing the way we fight cancer. Now’s your chance to make a difference.
You’ll use the latest revolutionary technology to help us develop unique approaches to combating cancer and putting our patients first.
You’ll be challenged, you’ll grow, and you’ll do important work.
And every day, when you go home, you’ll know that you gave your best to make the world a more hopeful place for those with cancer.
